Week of September 21st, 2020 | Vol. 9, Issue 38 |
|
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events
Quick Links
Contact Information
Managing Director
Business Development
Managing Director
Head of M&A and Capital Advisory
|
|
Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.
|
|
For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
|
|
MARKET REPORTS
Recent Materials Providing Insight Into Healthcare Related Industries
|
|
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
|
|
Project Aspen
Sell-side | Pharma Services | Multi-national contract manufacturing and packaging organization
Project Athena
Sell-side | Medical Device | Novel medical device for the treatment of pelvic organ prolapse
Project Vista
Out-partnering | Pharma | Seeking commercial partner for novel, liquid-format riluzole treatment of ALS
Project Seal
Buy-side | Pharma | Seeking Pain and CNS products as well as legacy/tail commercial pharma assets
Project Olympus
Sell-side | Pharma | Portfolio of generic injectable products
|
|
Gilead Sciences, Inc. has entered into a definitive agreement to acquire Immunomedics for approximately $21 billion in cash, which was approved by both the Gilead and Immunomedics Boards and is anticipated to close during 4Q20.
The acquisition provides Gilead with Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted accelerated approval by the U.S. FDA in April for the treatment of metastatic triple-negative breast cancer (mTNBC) in patients who have received at least two prior therapies for metastatic disease.
|
|
RECENT INDUSTRY TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
|
|
Pharma & Biotech
15 transactions totaling $22,226 million
Supplies, Equipment & Services
26 transactions totaling $513 million
Healthcare IT & Managed Care
11 transactions totaling $1,688 million
Healthcare Facilities & Distributors
8 transactions totaling $5 million
|
|
Pharma & Biotech
39 transactions totaling $1,995 million
Supplies, Equipment & Services
20 transactions totaling $363 million
Healthcare IT & Managed Care
18 transactions totaling $286 million
Healthcare Facilities & Distributors
2 transactions totaling $649 million
|
|
Pharma & Biotech
23 transactions totaling $878 million
Supplies, Equipment & Services
9 transactions totaling $1,728 million
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
1 transaction totaling $2 million
|
|
INDUSTRY TRADING COMPS
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
|
|
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.
For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table.
Note: data reflects prior week close.
|
|
|
RECENT INDUSTRY TRANSACTIONS
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
|
|
September 17, 2020 - Fierce Pharma
As part of an industrywide investigation that started in September 2019, New York’s Department of Financial Services (DFS) charged J&J with violations of two insurance laws relating to “fraudulent insurance acts” and “intentional misrepresentation of a material fact.” The charges follow cases DFS filed against Teva, Allergan, Endo and Mallinckrodt.
September 17, 2020 - Contract Pharma
Vaccinex Inc., a clinical-stage biotechnology company, has entered into a clinical collaboration agreement with Merck through a subsidiary, to evaluate the combination of Vaccinex’s investigational SEMA4D inhibitor, pepinemab, and Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in the treatment of patients with advanced, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
September 16, 2020 - Contract Pharma
Axovant Gene Therapies Ltd has signed a strategic partnership with Viralgen, a contract development and manufacturing organization (CDMO). Leveraging the technology platforms of AskBio, Viralgen is able to support all aspects of manufacturing for Axovant’s AAV programs, including large-scale manufacturing, fill-finish, and quality control in a GMP-certified environment designed to bring therapies to market as quickly as possible.
September 15, 2020 - Fierce Pharma
Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy is Takeda's next-gen cell therapies, and the company is now doubling down to get those products to market.
|
|
Welcome to Bourne, let's talk.
Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.
|
|
|
|
|
|
|
